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Abstract   
 
Background: Short-lived psychotic disorders are currently classified under “acute 
and transient psychotic disorders” (ATPDs) in ICD-10, and “brief psychotic 
disorder” (BPD) in DSM-5. The aim of this study is to review the existing literature 
and address the validity of ATPDs and BPD.  
 
Method: Systematic review of all papers identified through searches in Web of 
Science and published between January 1993 and December 2016. Reference lists 
in the located papers provided further sources.  
 
Results: A total of 295 articles were found and 100 were selected for inclusion in 
the review. There were only few studies about the epidemiology, vulnerability 
factors, neurobiological correlates and treatment of these disorders, particularly 
BPD was seldom a specific topic of investigation. The available evidence suggests 
that short-lived psychotic disorders are rare conditions and more often affect 
women in early to middle adulthood. They are also neither associated with 
premorbid dysfunctions nor characteristic family predisposition, while there seems 
to be greater contribution of environmental factors particularly in low- and middle-
income countries, and migrant populations. Follow-up studies report a favourable 
clinical and functional outcome, but case identification has proved difficult owing 
to high rates of transition mainly either to schizophrenia or, to a lesser extent, 
affective disorders over the short and longer terms. 
 
Conclusions: Although these findings argue against the validity of the above 
diagnostic categories, it is important that they are kept apart from longer-lasting 
psychotic disorders both for clinical practice and research. Close overlap between 
ATPDs and BPD could enhance the understanding of these conditions.   
 
 
 
 
Key words: acute transient psychosis, brief psychotic disorder, classification, 
diagnosis, nosology.  
 
 
 
 
 
 3 
 
1. Introduction  
Although the late 19th century Kraepelinian [1] dichotomy of dementia praecox, 
subsequently renamed schizophrenia, and manic-depressive insanity remains 
central to current psychiatric nosography, its inability to encompass all types of 
psychosis has made for great unclarity in classification of intermediate categories 
with adverse effects on psychiatric practice and research, particularly for short-
lived psychotic disorders that do not display prominent affective features [2].  
Framed in the wake of the WHO study on acute psychoses [3], the category of 
“acute and transient psychotic disorders” (ATPDs) was introduced in the ICD-10 
Classification of Mental and Behavioural Disorders (ICD-10) within the group of 
“schizophrenia, schizotypal and delusional disorders” [4]. ATPDs were 
characterized by: acute onset within 2 weeks; polymorphic, schizophrenic or 
predominantly delusional syndromes; and association with stressful events (Table 
1). Acute polymorphic psychotic disorder (APPD) refers to earlier diagnostic 
concepts such as bouffée délirante and cycloid psychosis [5–7], featuring varied 
delusions, hallucinations, perceptual changes, perplexity and emotional turmoil 
shifting daily or even faster, and can include schizophrenic symptoms. Complete 
remission within 1 or 3 months sets the ATPD subtypes with schizophrenic 
symptoms apart from schizophrenia, as the ICD-10 diagnosis of schizophrenia 
requires at least 1 month’s duration, and the subtypes with polymorphic or 
delusional features from persistent delusional disorder, which lasts longer than 3 
months.  
The Diagnostic and Statistical Manual of Mental Disorders (DSM) has, since its 
fourth edition [8], listed “brief psychotic disorder” (BPD); diagnostic criteria have 
remained unchanged in DSM-5 including sudden onset of florid psychotic 
symptoms such as delusions, hallucinations, disorganised speech, and grossly 
disorganised or catatonic behaviour lasting less than 1 month [9]. It is also 
possible to specify if BPD follows marked stressors or arises in the post-partum 
period. Although ATPDs and BPD bear some similarity, comparative studies 
revealed that the two categories overlap only in part owing to differences in onset, 
duration and symptomatology [10–15].   
It is more than 20 years since ATPDs and BPD have appeared in official psychiatric 
classifications, but their distinctive features remain uncertain [15,16]. The aim of 
this paper is to review the literature and address the validity of ATPDs and BPD, 
then to discuss implications for future classification, clinical practice and research.  
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2. Methods  
We conducted a two-step literature search following the guidelines for systematic 
reviews and meta-analysis provided by the PRISMA statement [17]. Web of 
Science searches were made using the terms: acute polymorphic psychosis OR 
acute polymorphic psychotic disorder OR non-affective acute remitting psychosis 
OR acute transient psychosis OR acute transient psychotic disorder) OR "acute 
brief psychosis" OR "acute brief psychoses" OR "brief psychotic disorder" OR "brief 
psychotic disorders". The search included works in English, French and German, 
published in peer-reviewed journals between 1 January 1993 and 31 December 
2016. Reference lists in the located papers provided further sources. Selection of 
relevant papers was restricted to studies including at least 10 cases, and diagnosis 
coded using ICD-10 and DSM-IV/DSM-5 criteria. In addition, follow-up studies 
required a minimal duration of 12 months, and clearly defined measures of 
outcome and/or diagnostic stability. Where publications reported overlapping data 
the most informative or recent were selected.  
To assess the validity of ATPDs and BPD, the available evidence was reviewed 
according to Kendler [18] in 3 main classes of potential validators: a) antecedent 
validators (i.e. demographic features, family aggregation, premorbid and 
precipitating factors); b) concurrent validators (biological markers, psychological 
tests, genetics, symptom measures); and c) prognostic validators (diagnostic 
stability, course, outcome and response to treatment).  
 
 
 
3. Results  
A total of 295 papers were found, and 100 were selected for inclusion in the 
systematic review. The PRISMA flow diagram illustrates the number of papers 
identified, those selected and excluded, and the reasons for exclusion (Figure 1).   
 
3.1. Antecedent validators  
 
3.1.1. Demographic factors of ATPDs  
The annual incidence of ATPDs ranges from 3.9 in the UK to 9.6 in Denmark per 
100000 population, and the 2-year and 3-year rates for those with unchanged 
diagnosis are 6.7 and 1.4 respectively [19–21] (Table 2). ATPDs seem to affect 
more frequently women or both genders almost equally [21–24], and the mean 
age of onset is intermediate between schizophrenia and bipolar disorder [21]. 
 5 
Male incidence picks early in the mid-20s, yet the highest rates for women occur 
ten years later and are greater than those for men over 40 years [21,24].   
There are also differences in age and sex distribution across the ATPD subtypes: 
APPD is more common in women and arises later than both subtypes with acute 
schizophrenic features, which predominate in young males [25]. No gender 
difference was found in acute predominantly delusional disorder, which has a later 
onset than any ATPD subtype [21].   
Reports on ATPD prevalence are also varied ranging from 5.8% to 19.0% 
[19,20,22,23,26], with greater rates often observed in low and middle-income 
countries, where these conditions are reported to have an earlier age of onset 
than in high-income ones [27–31].   
Further evidence suggests that ATPDs have an increased mortality from both 
natural and unnatural causes [32,33]. The mortality risk of ATPDs is nearly twice as 
high in males, and similar to that for schizophrenia, while there seems to be a small 
but significant higher overall and natural-cause mortality than bipolar disorder. 
Suicide is the major cause of premature death and accounts for a quarter of excess 
mortality [33]. Two reports on suicidal behaviour estimated rates of 36% and 55%, 
with the highest risk during the acute phase characterised typically by rapidly 
changing and variable delusions ad hallucinations, agitation and mood instability 
[34,35].  
In addition, late-onset ATPDs (over 60 years) are associated with a high risk not 
only of mortality but also of dementia; in these cases a differential diagnosis from 
delirium proves often difficult [36].   
 
3.1.2. Predisposing factors of ATPDs 
Das et al. [37] found that the risk of ATPDs was 3 times higher in first-degree 
relatives of patients with ATPDs than in family members of schizophrenic 
patients, while the risk of schizophrenia was significantly increased in the family 
of patients with schizophrenia. A later study reported that ATPD patients with a 
family history of mental disorder experienced fewer life events before illness 
onset than those without family psychiatric antecedents; in keeping with the 
stress-vulnerability model, family predisposition would produce its effect by 
increasing emotional reactivity, which renders subjects less likely to cope with 
adverse events [38].  
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Jørgensen et al. [39] found that almost two thirds of their cases with ATPDs had 
an additional diagnosis of personality disorder; this rate dropped one year later 
probably because personality changes resulted either from psychotic 
decompensation or psychotropic treatment as most patients recovered and/or 
discontinued medication.  
Marneros et al. [23] observed higher psychiatric morbidity in family members of 
patients with ATPDs than in relatives of healthy controls, but no significantly 
raised risk of psychotic disorder. ATPD patients also exhibited lower neuroticism 
and higher extroversion and conscientiousness than those affected with 
schizophrenia and/or schizoaffective disorder; in addition, they were more likely 
to have a better premorbid social functioning than schizophrenic patients [40]. 
There seems also to be a close relationship between speed of onset and duration 
of untreated psychosis (DUP), and short DUP would be consistent with diagnosis 
of ATPDs [41].   
Furthermore, a population-based family study [42] revealed that the risk of ATPDs 
was increased if patients had not only first-degree relatives affected with ATPDs, 
but also with bipolar disorder, and particularly with schizophrenia; yet the risk of 
schizophrenia and bipolar disorder was markedly high if patients with 
schizophrenia and bipolar disorder have family members with the same condition. 
As regards the ATPD subtypes, the risk of APPD was high in patients having first-
degree relatives with either ATPDs or schizophrenia; schizophrenia in family 
members had the greatest effect on those subtypes featuring schizophrenia-like 
symptoms; and bipolar disorder did not increase significantly the risk for any 
ATPD subtype.  
 
3.1.3. Precipitating factors of ATPDs 
Social and cultural factors are more likely to be associated with ATPDs in low- and 
middle-income countries [27,38,43,44] than in high-income ones, where only a 
relatively small number of cases are triggered by life events [10,19,23,45–47]. 
ATPDs seem also more common in migrant populations [48,49]. Lau et al. [50] 
reported that the risk of ATPDs in Hong-Kong is two times higher in foreign 
domestic workers; homesickness and marital problems were the most frequent 
stressful events. These findings lend support to reports from European countries 
showing that first- and second-generation immigrants have a greater risk of 
ATPDs than native populations [51].  
Further evidence indicates that stressful events are more often associated with 
ATPDs than schizophrenia, persistent delusional disorder, schizoaffective disorder 
or manic disorder [23,44,52–54]. Examination of 1904-1905 Welsh religious 
revival revealed a significant increase in hospital admissions with brief 
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polymorphic psychotic symptoms, pointing out that these conditions are part-
caused by environmental factors [55].   
 
3.1.4. Demographic and vulnerability factors for BPD  
No epidemiological study has yet been conducted; available data suggest that BPD 
is more common in women and accounts for 2.0-7.0% of individuals with a first 
episode of psychosis [56–60]. The lifetime prevalence of BPD is estimated at 
0.05% [61]. It was also found that BPD is not associated with family history of 
schizophrenia, and more often is triggered by emotional and socio-cultural factors 
than schizophrenia and/or schizophreniform disorder [62]. Furthermore, patients 
with BPD exhibit fewer schizoid and schizotypal traits, and enjoy better social and 
occupational functioning than those with schizophrenia [63].  
 
 
3.2. Concurrent validators  
 
3.2.1. Symptom measures of ATPDs  
Despite variations in symptom profile, ATPDs are more likely to be characterised 
by acute onset of fleeting polymorphic features such as delusions and 
hallucinations, mood changes, anxiety, agitation, insomnia and fewer negative 
symptoms than schizophrenia, persistent delusional disorder and schizoaffective 
disorder [23,53,64,65]. Jäger et al. [53] reported that patients with ATPDs have 
shorter hospital admission and achieved more rapidly functional recovery than 
those diagnosed with schizophrenia, delusional disorder and/or schizoaffective 
disorder. Attempts to differentiate schizophrenia from ATPDs on the basis of 
Schneider’s first-rank symptoms (FRS) failed because they occur in both 
conditions; only negative symptoms seem to be indicative of schizophrenia [53]. 
There are also diversities in the frequency of ATPD subtypes featuring polymorphic 
[23,27,64,66], schizophrenic [22,45,47], and predominantly delusional symptoms 
[19,46].  
The field trials of ICD-10 showed that many ATPD subtypes failed to achieve 
established standards of reliability [67]. More to the point, little evidence supports 
the division of acute polymorphic psychotic disorder into subtypes “with” or 
“without” schizophrenic symptoms based on 1 or 3 months’ duration, and acute 
predominantly delusional disorder is a diagnosis by exclusion from polymorphic 
psychotic disorder, persistent delusional disorder and schizophrenia. In addition, 
changes between clinical and research diagnosis of ATPDs, the latter made using 
standardized instruments, suggest little specificity [68].   
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3.2.2. Neurobiological factors of ATPDs  
Apart from differences in amplitude of auditory P300 event-related potentials from 
schizophrenia and healthy controls [69], neither structural nor functional brain 
changes have been observed in ATPDs. Pepplinkhuizen et al. [70] described a 
series of metabolic alterations in amino acid pathways by analogy with psychedelic 
drug induced-psychosis; and Bach et al. [71] reported higher serum levels of 
bilirubin than in schizophrenia and/or schizoaffective disorder. Rotting et al. [72] 
examined EEG recordings of ATPD patients, but no significant change was found.  
More recently, Kanazawa et al. [73] conducted a genome-wide association study of 47 
cases with “atypical psychosis”, a close variant of ATPDs described in Japan [74], and 
reported that the putative genes overlap towards those for schizophrenia.  
 
3.2.3. Symptom measures and cognitive dysfunction of BPD  
Korver-Nieberg et al. [58] observed shorter duration, less emotional distress, 
fewer negative and disorganized symptoms, higher quality of life and social 
functioning in BPD than schizophrenia, schizophreniform disorder, schizoaffective 
disorder and/or unspecified psychosis. Moreover, Lyne et al. [75] found that 
negative symptoms are rare in BPD, while resulted significantly more frequent in 
schizophrenia and related disorders.  
Although symptoms seem to be less severe in BPD than with in schizophrenia 
and/or schizophreniform disorder [62], cognitive impairment is common to 
psychotic patients, but no deficit in attention, memory or executive function was 
found [63,76]. Yet, BPD patients improved more rapidly, particularly in processing 
speed, than those with schizophrenia, schizophreniform disorder and/or 
unspecified psychotic disorder after six months [77].  
 
 
3.3. Prognostic validators  
 
3.3.1. Diagnostic stability, course and outcome of ATPDs  
The course and outcome of ATPDs have been mapped by about 25 papers with 
follow-up periods from 1 to 20 years (Table 3). The overall stability of ATPDs was 
estimated at around 65% on average after 4.5 years [78]. Women are significantly 
less likely than men to develop another diagnosis [10,19,46,66,78–80].  The risk of 
relapse based on findings from a large meta-analysis was 13% after 6 months, 
30% after 1 year, 38% after 2 years, and 54% after 3 or more years [81]. The 
greatest diagnostic variability tended to occur in the 24 months following the initial 
episode mainly either to schizophrenia and related disorders or affective disorders 
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[24,46]. In addition, there were 30%-60% of patients with ATPDs who enjoyed 
stable symptomatic remission and/or discontinued medication [10,22,45,82]. They 
also had better clinical and functional outcomes than patients with schizophrenia, 
schizoaffective disorders and/or persistent delusional disorder over the short and 
longer terms [23,65,83].   
Besides female gender, good premorbid adjustment, abrupt onset, short DUP and 
early remission within 4 weeks seem to predict favourable outcome and/or 
diagnostic stability in ATPDs [19,27,45,54,84], yet the risk of conversion into 
schizophrenia or schizoaffective disorder seem to be associated with family history 
of schizophrenia, male gender, age of onset below 35 years, longer hospital 
admission, and Schneider’s FRS [24,45,64,66,80,85,86].   
Among the ATPD subtypes, APPD showed a higher diagnostic consistency than 
those featuring acute schizophrenic or predominantly delusional symptoms, which 
were more likely to herald schizophrenia and related disorders 
[25,27,45,47,66,87].   
Further evidence suggests that ATPDs in low- and middle-income countries have 
low rates of recurrence and high temporal stability ranging from 54% to 100% 
[27,43,88–90]. For example, Sajith et al. [27] reported that nearly three quarters 
of their series of cases did not develop another diagnosis, and more than half 
experienced no relapse over three years. 
 
3.3.2. Diagnostic stability, course and outcome of BPD  
There were 10 studies on course and outcome of BPD with follow-up periods from 
15 months to 10 years (Table 4). Over the short term, some surveys found that 
about two thirds of cases with BPD do not develop another diagnosis and/or 
remitted rapidly [57,91–93], while others reported far higher transition rates to 
schizophrenia and related disorders [56,94,95]. The latter findings compare 
favourable with longer-term follow-up studies showing that many cases with BPD 
evolved into more severe and persistent affective and/or psychotic disorders 
[59,60].  
Moreover, Pillmann et al. [96] found that patients admitted with BDP experience 
high rate of relapse but they have significantly better clinical and social outcome 
than schizophrenic patients. In keeping with meta-analytical findings the overall 
stability of BPD reached 45% on average within 4.5 years [78], and the risk of 
recurrence was estimated at 20% after 6 months, 31% after 1 year, 46% after 2 
year, 53% after 3 or more years [81].  
 
3.3.3. Response to treatment of ATPDs  
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Khanna et al. [97] compared low and high dose haloperidol in 40 patients with 
ATPDs, but no significant difference in achieving symptomatic remission was 
observed over four weeks. Chaudhury et al. [98] reported that risperidone 
induced fewer extrapyramidal symptoms and proved more effective than 
haloperidol in reducing both positive and negative symptoms in the early stage of 
treatment. Agarwal and Sitholey [99] conducted a six-week trial of olanzapine in 
23 paediatric patients with ATPDs showing symptom remission and relatively few 
side effects such as dry mouth, sedation, increased appetite and weight gain. 
 
3.3.4. Response to treatment of BPD  
Ehlis et al. [100] noted that atypical antipsychotics bring about a positive effect on 
prefrontal brain functions in cases with BPD using neurophysiological techniques.  
 
 
4. Discussion  
To our knowledge, this is the first systematic review that addresses the validity of 
ICD-10 ATPDs and DSM-5 BPD. It brings about a better understanding of these 
diagnostic categories and offers an opportunity to reconsider how they have been 
differentiated from schizophrenia and related disorders, though limited data is 
available about the epidemiology, vulnerability factors, neurobiological correlates 
and treatment, particularly BPD has failed to encourage research.    
 
4.1. Antecedent validity factors  
The existing studies suggests that ATPDs and BPD are rare mental disorders and 
more often affect women with onset in the early-middle adulthood [19–21,24]. 
Higher rates have been reported in Scandinavia, in migrant populations and in 
some developing countries, where these conditions are more often triggered by 
emotional and socio-cultural factors, owing to the lingering importance of reactive 
psychosis and to an unwillingness to diagnose schizophrenia in the first episode of 
psychosis [27,28,38,48–52,101]. Yet cases with schizophrenia show earlier age of 
onset and are prevalent in males [102].  
Similar conditions such as the “non-affective acute remitting psychoses” described 
by Susser et al. [103] have an uneven geographical distribution with a greater 
incidence in low- and middle-income countries, mainly in women. These disorders 
have been frequently observed in the wake of stressful events, fever or systemic 
infections, and do not conform either to remitting schizophrenia or atypical 
affective disorders in clinical profile, course and outcome [104–109], but seldom 
fulfil the diagnostic criteria for both ATPDs and BPD having a modal duration of 2-
4 months [110,111].  
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There also is in ATPDs an increased risk of premature mortality from both natural 
and unnatural causes, similarly high to that for schizophrenia [33,36].  
Further evidence suggests that short-lived psychotic disorders are neither 
associated with premorbid dysfunctions nor characteristic predisposition 
[19,23,37,39,40]. Family psychiatric morbidity has a smaller impact on ATPDs 
than on schizophrenia and bipolar disorder; while ATPDs are likely to have a 
kinship to schizophrenia [42], at least partly attributable to the fact that this 
category includes clinical subtypes which are set apart from schizophrenia only by 
temporal criteria. The relationship between ATPDs and affective disorders remains 
uncertain [23,42,54].  
As regard the clinical subtypes encompassed by ATPDs, APPD is more common in 
females and occurs later than the subtypes with schizophrenic symptoms [25].   
 
4.2. Concurrent validity  
It would appear that ATPDs and BPD have the following commonalities: acuteness 
of onset, variable clinical profile, fewer negative symptoms and shorter duration 
for episode than schizophrenia and related disorders [23,52,53,62,75,96,111]. 
However, no convincing evidence of neurobiological correlates - other than 
changes in amino acids or bilirubin metabolism, auditory P300 amplitude and 
putative genetic alterations overlapping with those for schizophrenia - fail to 
support the concurrent validity of these disorders. It has been suggested that 
acute psychosis in black immigrants would arise from interaction between social 
adversities and a vitamin D deficit [112].   
 
 
4.3. Prognostic validity 
In absence of aetiological factors and biological markers, the validity of diagnostic 
categories hinges mainly on their predictive power, as it is expected that they 
prove useful in making predictions of treatment and outcome. Follow-up studies 
report quite variable patterns of course and outcome for both ATPDs and BPD, 
pointing out that the risk of recurrence is high with subsequent transitions either 
to schizophrenia and related disorders or, to a lesser extent, affective disorders 
[10,19,24,46,56,59,60,78,81,95]. Apart from female gender, the other factors 
predicting favourable outcome and/or diagnostic stability in ATPDs such as good 
premorbid adjustment, short DUP and early remission need to be replicated.  
A distinctive feature of ATPD patients is the lack of cognitive deterioration and 
impaired functioning; they fare better than those with schizophrenia, 
schizoaffective disorder and/or delusional disorder, though a relatively small 
number enjoyed stable remission and discontinued medication [10,22,45,65,82]. 
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Moreover, APPD has a better course and higher diagnostic stability than the 
subtypes featuring schizophrenic or predominantly delusional features 
[25,27,45,66].  
There may also be variations in course and outcome of ATPDs between high-income 
countries and low- and middle-income ones, where these disorders tend to have lower 
rates of relapse and diagnosis changes, and are more often associated with 
sociocultural factors [27,43,88–90]. This raises the question of whether environmental 
factors mediated by emotion-driven pathways not only trigger the onset [38], but also 
make the outcome of acute psychoses more favourable, yet insidious-onset psychosis 
would be associated with cognitive impairment, negative symptoms and poor outcome 
[113,114].   
 
4.4. Implications for clinical practice and research  
ATPDs and BPD may cause difficulty in assessment and treatment. First, it is not 
easy to identify cases in practice because of the lack of distinctive clinical features 
and too restrictive temporal criteria. Differential diagnosis includes early 
schizophrenia or affective psychosis, substance-induced psychosis, psychosis due 
to brain dysfunction or general medical conditions, and simulation psychosis.  
Secondly, follow-up studies report a tendency to recur and high rates of transition 
to longer-lasting psychotic and affective disorders. These are probably the reasons 
why ATPDs and BPD have been often left out from epidemiological surveys of first-
episode psychosis, and hence the frequency of those who experience acute onset, 
florid psychotic symptoms and early remission remains uncertain.  
Thirdly, individuals with acute psychosis usually require hospital admission owing 
to disorganized behaviour, impaired insight, aggressive and/or suicidal acts; in 
these cases, antipsychotic medication is prescribed not only for acute 
symptomatology but also for prevention of recurrences [16]. In absence of any 
evidence and guidance [15,16,115], high-dose or prolonged usage of 
antipsychotics need to be considered cautiously, as they can induce a number of 
adverse effects; atypical antipsychotics are also more likely to be associated with 
increased risk of cardiovascular disease, diabetes and premature mortality [116]. 
It will be rewarding for future treatment trials to identify the most appropriate 
therapy for patients with acute psychosis.  
Further research is expected to address the relationship of ATPDs, BPD and 
operational definitions currently used to describe individuals “at high risk” of 
psychosis such as “brief limited intermittent psychotic symptoms” (BLIPS/BIPS) 
[117]. Preliminary findings indicate that BLIPS tend to conform more to the ATPD 
subtypes with schizophrenic features probably because the Schneiderian FRS are 
common to both conditions and young males were preponderant in the sample 
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studied [118]. In addition, BLIPS are reported to have the same risk of recurrence 
as ATPDs and BPD, yet the risk for first-episode schizophrenia is significantly 
higher over the short and longer terms [81].  
 
4.5. Implications for psychiatric classification 
In view of the scepticism aroused by the heterogeneity of ATPD category, the 
proposed revision for the forthcoming ICD-11 would restrict it to APPD with a 
duration shorter than 3 months, while the remaining subtypes with schizophrenic 
and predominantly delusional symptoms would be redistributed into other classes 
of the newly renamed F2 section “schizophrenia spectrum and other primary 
psychotic disorders” [119]. These changes would bring the ATPD category closer 
to non-affective acute remitting psychoses [110], but it seems questionable 
whether APPD may be itself a reliable diagnosis owing to intrinsic instability (that 
is, symptoms change in type and intensity daily or even more frequently). Little 
evidence also support the continuity between APPD and the clinical concepts to 
which it refers such as bouffée délirante and cycloid psychosis [120–123].   
A more pragmatic solution, as akin to the DSM category of BPD, would be to 
select the clinical features that lend themselves to easier assessment and hence 
offer at least greater diagnostic reliability such as acute onset, florid psychotic 
symptoms and brief duration [15,110]. Close overlap between ATPDs and BPD 
might have benefits not only for clinical practice, but also for research, where 
diagnostic accuracy is essential. 
 
4.6. Limitations  
Little data about antecedent, concurrent and predictive factors precluded accurate 
assessment of BPD validity. Situation is different in ATPDs: while earlier studies 
were small and probably not powered enough to produce meaningful findings, 
recently published papers included larger samples, but differences in case 
ascertainment, age cut-offs, study design, cultural setting, length of follow-ups, 
and distribution of ATPD subtypes make comparison difficult. Another possible 
issue affecting concurrent and prognostic validity hinges on the paucity of 
neurobiological findings, prospective cohort studies, and treatment trials.  
 
 
5. Conclusions  
These findings suggest that ATPDs and BPD have clinical and epidemiological 
which are likely to distinguish them from schizophrenia and related disorders, but 
the lack of neurobiological correlates, high risk of recurrence and subsequent 
diagnosis change argue against their validity. Nonetheless, it is desirable that 
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these categories are revised and kept separate from longer-lasting psychotic 
disoders both for clinical practice and research.  
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Figure 1  PRISMA flow diagram showing the number of papers identified, those selected and 
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Table 1 ICD-10 F23 Acute and transient psychotic disorders (ATPDs) and DSM-5 298.9 Brief 
psychotic disorder (BPD)  
 
 
 ATPDs BPD 
Symptoms Polymorphic, schizophrenic and 
predominantly delusional≠ 
Delusions, hallucinations, disorganized 
speech, grossly disorganized or catatonic 
behaviour 
Onset Acute onset within 2 weeks*  Not specified 
Duration  1 or 3 months 1 day to less than 1 month with full 
return to premorbid functioning 
Specify if with Acute stress within 2 weeks Marked stressor or onset within 4 weeks 
post-partum 
Exclusion Substance-induced psychosis, organic 
disorders, manic and depressive disorder 
Affective disorder, substance-induced 
psychosis, psychosis due to medical 
conditions, psychotic disorder NOS 
 
≠ATPD category comprises six subtypes: ‘acute polymorphic psychotic disorder’ (F23.0), which can 
include schizophrenic symptoms (F23.1); ‘acute schizophrenia-like psychotic disorder’ (F23.2); ‘acute 
predominantly delusional psychotic disorder’ (F23.3); and ‘other’ and ‘unspecified’ acute and transient 
psychotic disorders (F23.8-9).  
 
*Acute onset is defined as a change from a state without psychotic features to a clearly psychotic 
state within 2 weeks or less. It is also possible to specify “abrupt onset within 48 hours”.   
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Table 2 Antecedent and concurrent validators for ICD-10 acute and transient psychotic 
disorders (ATPDs)  
 
Study Demographic features 
Singh et al. 
[19] 
32/162 cases of FEP had ATPDs (19%); incidence 3.9/100000. After 3 years, this rate 
dropped to 1.4 with a reversal of sex-rate ratio for women.    
Castagnini et 
al. [20] 
ATPD incidence 9.6 /100000 over 15 years based on data from DPCR; mean age 
significantly later in women than men (46.2 vs 37.8 years). 
 
Castagnini & 
Foldager [21] 
All in- and out-patients aged 15-64 years enrolled in the DPCR with ATPDs (n = 
3350), SZ (n = 4576), and bipolar disorder (n = 3200) in 1995-2008; ATPD 
incidence 6.7/100000, mean age intermediate between SZ and bipolar disorder, 
no sex difference.  
 
Queirazza et 
al. [24] 
Consecutive admissions (n = 2923) from the Scottish Morbidity Record in 1997-2010. 
ATPD incidence 4.1/100000, significantly greater in men than women (4.6 vs 3.6); 
mean age at onset higher in women than men (41.8 vs 33.8 years).  
Esan & Fawole 
[30] 
First admissions with ATPDs (n = 124) in Nigeria; overall mean age 29.5 years; no sex 
difference.  
 
Mehta et al. 
[31] 
Patients admitted with ATPDs (n = 185) in India; no significant sex difference; mean 
age 27.0 years; most cases were married, unemployed and/or living in rural areas.    
   
Castagnini & 
Bertelsen [32] 
87/503 (17.3%) patients with ATPDs had died (70% aged over 65 years) over 6-
years, accounting for excess morality from both natural (SMR 2.9) and unnatural 
causes (SMR 9.2).   
 
Castagnini et 
al. [33] 
ATPD mortality between 15 and 64 year olds significantly raised from natural (SMR 
3.9) and unnatural causes (SMR 7.3); particularly suicide (SMR 14.7). Mortality risk of 
ATPDs (SMR 4.7) was twice as high in men and similarly high to SZ. 
 
Kørner et al. 
[36] 
ATPDs over 60 years associated with a high risk of mortality and dementia.   
 Family aggregation and premorbid functioning 
Marneros et 
al. [23] 
Family members of ATPD patients (n= 42) had higher psychiatric morbidity than FDRs 
of healthy controls, but no significantly raised risk of psychotic disorder. 
Das et al. [37] Family study comparing ATPDs (n = 40) and SZ (n = 40); ATPD risk was 3 times 
higher in FDRs of ATPD patients; yet the risk of SZ was lower in the family of 
ATPD patients than those with SZ.  
Das et al. [38] 13/44 (33%) cases with ATPDs were triggered by acute stress, and 11 had a 
family history of mental disorder; they experienced fewer life events than those 
without family psychiatric antecedents.  
Jørgensen et 
al. [39] 
Nearly two-thirds of ATPD patients (n = 51) had a diagnosis of personality disorder; 
this rate dropped one year later. 
Pillmann et al. 
[40] 
Comparative study of ATPDs (n= 42), SZ, schizoaffective disorder and healthy controls 
using the 5-NEO Factor Inventory. No significant difference between ATPD patients and 
healthy controls; yet those with schizoaffective disorder and SZ had higher neuroticism 
and lower extroversion and conscientiousness.  
Castagnini et 
al. [42] 
Genetic epidemiological study of all cases enrolled in the DPCR with ATPDs (n = 2537), 
SZ (n = 10639), and BD (n = 5292) in 1996-2008; family psychiatric morbidity effects 
a smaller increase of risk for ATPDs (RR 1.6) than for both SZ and bipolar disorder.  
 Precipitating factors/social adversities 
Krahl & ATPDs more frequently diagnosed in southeast Asian migrant workers in Malaysia than 
Table
Hashim [48] native populations.  
Shaltout et al. 
[49] 
ATPDs were preponderant among young foreign workers in hospital admissions from 
Qatar.   
Lau et al. [50] Foreign domestic workers in Hong-Kong have a risk of ATPDs twice as high as local 
populations.  
Alexandre & 
Ribeiro [51] 
ATPDs more common in first- and second-generation black immigrants from African 
Portuguese speaking countries; most were males and had an earlier illness onset than 
indigenous population.    
Linden et al. 
[55] 
Historical report showing significantly increased admission rates for short-lived 
psychotic disorders linked to 1904-1905 Welsh religious revival.   
 Symptom measures 
Marneros et al. 
[23] 
Consecutive admissions with ATPDs (n= 42) and control groups with SZ, and 
schizoaffective disorder. ATPDs featured more often changing and varied delusions, 
anxiety and mood instability.    
Pillmann et al. 
[40] 
Comparative study of ATPDs (n = 41) and delusional disorder (n = 43). ATPDs display 
varied and fleeting symptoms and fared significantly better over a mean follow-up of 
10-12 years.     
Esam & Fawole 
[52] 
Cross-sectional study of hospital admissions with ATPDs (n = 124) and SZ (n = 243) 
in Nigeria; anxiety and excitement more prevalent in ATPDs.   
Jäger et al. 
[53] 
Cross-sectional study of patients with SZ (n = 951), ATPDs (n = 116), delusional 
disorder (n = 51), and schizoaffective disorder (n = 354). ATPDs had fewer negative 
symptoms, shorter duration and better functioning than SZ.    
Kampman et 
al. [68] 
Little specificity of ATPD diagnosis probably due to unwillingness to diagnose SZ in the 
first-episode of psychosis.    
 Neurobiological factors 
Sahoo et al. 
[69] 
Differences in auditory P300 amplitude from schizophrenia and healthy controls.  
Pepplinkhuizen 
et al. [70] 
Polymorphic psychotic symptoms associated with metabolic changes in amino acid 
pathways.  
Bach et al. 
[71] 
Higher serum levels of bilirubin in ATPD patients than those with SZ and/or 
schizoaffective disorder.  
Rotting et al. 
[72] 
No significant difference in EEG recordings between ATPD patients and those with SZ 
and/or schizoaffective disorder.  
Kanazawa et 
al. [73] 
Genome-wide association study of 47 cases with atypical psychosis showing that 
putative genetic alterations overlapped with those for SZ. 
 
ATPDs: acute and transient psychotic disorders; DPCR: Danish Psychiatric Central Register; SMR: 
standardized mortality risk; FEP: first-episode psychosis; SZ: schizophrenia.  
 
Table 3 Prognostic validators for ICD-10 acute and transient psychotic disorders (ATPDs)  
 
Study N/F-up  Length  Diagnostic stability, course and outcome 
Jørgensen et al. 
[10] 
51/46  1 y 52% ATPDs (1/3 recurrent course), 17% changed to SZ 
and/or delusional disorder, 8% affective disorders.  
Singh et al. [19] 32  3 y FEP study: 35% ATPDs (2/3 recurrent), 35% SZ or 
delusional disorder, 19% affective disorders, 9% other. 
Female gender and good premorbid adjustment predicted 
diagnostic stability. ATPD mean GAS score >70.    
Jäger et al. [22] 94/73  3-7 y ATPDs: 42% single episode, 58% recurrent course, 12% 
persistent impairment. Negative and/or depressive 
symptoms associated with unfavourable prognosis.  
Queirazza et al. [24] 2923 4-7 y Case-record study; 54% ATPDs; 13% SZ, 12% affective 
disorders. Age below 30 years, male gender, and longer first 
admission associated with increased risk and earlier 
transition to SZ 
Castagnini & 
Foldager [25] 
5426  9.3 y Case register study; APPD more common in women, higher 
stability and lower rates of recurrence than the remaining 
subtypes with schizophrenic or delusional features.  
Sajith et al. [27] 45  3 y Prospective study of APPD; 73% same diagnosis, 22% BD, 
4% unspecified psychosis; admission shorter than 1 month, 
and abrupt onset predicted temporal stability.  
Okasha et al. [43] 50  1 y WHO study on acute psychoses (Egyptian cohort); 74% had 
ATPDs and 54% did not change diagnosis (2/3 full 
remission, 14% recurrent course); 20% SZ and 26% 
affective disorders. 
Aadamsoo et al. 
[45] 
153/107 2 y Prospective study; 52 (49%) ATPDs (2/3 full remission, GAF 
score >70; 30% discontinued medication), 50% 
SZ/schizoaffective disorder. APPD more common in women, 
later age of onset and fewer changes to SZ.  
Castagnini et al. 
[46] 
5426  7.3 y Case register study: ATPD overall stability 45% (62% by 1 
year, 56% by 2 years, 48% by 5 years); SZ and related 
disorder 31%, affective disorders, 13%, other 8%. Women 
were less likely to develop another diagnosis.  
Rusaka & Rancans 
[47] 
294/144  5.6 y Retrospective study: 15% ATPD recurrent course, abrupt 
onset, polymorphic symptoms and anxiety associated with 
diagnostic stability.  
Castagnini et al. 
[54] 
47 1 y WHO study on acute psychoses (Aarhus cohort); 47/91 
ATPDs: 28 (60%) did not change diagnosis, 28% affective 
disorders, 13% SZ/schizoaffective disorder. Nearly all 
patients with unchanged diagnosis had full remission. 
Heslin et al. [60] 29 8 y FEP study; ATPDs: 4 (17%) retained the same diagnosis, 7 
(29%) SZ, 6 (25%) affective disorders, 6 (25%) other.  
Suda et al. [64] 25  9.7 y Case-note study; 15 (60%) ATPDs, 40% SZ; ATPD episodic 
course and longer remission than cases converting to SZ. 
Salvatore et al. [66] 55 2 y FEP study; ATPDs: 62% did non change diagnosis; 30% 
polymorphic psychotic disorders vs 72% schizophrenia-like 
disorder evolved into longer-lasting affective or psychotic 
disorders.  
Remberk et al. [79] 46 8 y Prospective EOP study; ATPD diagnosis and female gender 
associated with better clinical and functional outcome than 
SZ.   
Table
Björkenstam et al. 
[80] 
868 5 y Swedish case register study; 41% ATPDs, 22% 
SZ/schizoaffective disorder, 8% BD, 29% other. The risk of 
conversion into SZ or BD was twice as high for those with 
family members with SZ or BD.  
Pillmann & Marneros 
[82] 
42/39  7 y Prospective study; 54% ATPDs (3/4 recurrent episodes), 
30% affective disorders, 18% SZ and schizoaffective 
disorder. ATPDs: 30% stable remission discontinued 
medication (GAS score > 80).  
Möller et al. [83] 30 15 y First admission psychosis study; ATPDs: 30% single episode, 
50% remitting course and 20% chronic course. ATPDs fared 
better than SZ and delusional disorder.  
Chang et al. [84] 17 5 y FEP study: 35% ATPDs, 35% SZ, 12% schizoaffective 
disorder and 18% BD.  
Rusaka & Rancans 
[85] 
102/41  2.2 y Prospective study: 20% ATPD recurrent course; thought 
disorder predicted transition to SZ.  
Poon & Leung [86] 87 20 y Case-note study of first admissions in Hong Kong; one third 
unchanged diagnosis; diagnostic changes associated with 
young age, family psychiatric morbidity and high rates of 
recurrence.  
Abe et al. [87] 16  12 y Retrospective study; 10 (63%) ATPDs (2/3 recurrent 
course), 30% SZ and personality disorder. 
Amini et al. [88] 10 1 y ATPD diagnosis remained unchanged, only one case 
relapsed.  
Thangadurai et al. 
[89] 
87 13 m Case-note study: 64% ATPDs, 11% recurrent course; 26% 
SZ, 9% affective disorders.  
Narayanaswamy et 
al. [90] 
57/43  2 y Retrospective study: 63% ATPDs (50% recurrent course); 
21% BD, 16% SZ or unspecified psychosis.  
 Response to treatment 
Khanna et al. [97] 40 4 wk Clinical trial comparing low (5mg) and high (20 mg) dose 
haloperidol; no significant difference in achieving 
symptomatic remission.  
Chauhdury et al. 
[98] 
30 4 wk Randomized trial comparing haloperidol and risperidone; the 
latter proved more effective in reducing both positive and 
negative symptoms in the early phase of treatment.  
Agarwal & Sitholey 
[99] 
23 6 wk Open trial of olanzapine in patients aged 6-16 years showing 
symptomatic improvement and relatively few side effects.   
APPD: acute polymorphic psychotic disorder without schizophrenic symptoms; BD: bipolar disorder; EOP: 
early onset psychosis; FEP: first episode psychosis; GAF/S: Global Assessment of Functioning/scale; SZ: 
schizophrenia.  
 
Table 4 Antecedent, concurrent and predictive validators for DSM-5 Brief psychotic disorder  
 
Study Vulnerability factors  
Ngoma et al. 
[62] 
BPD is not associated with family history of SZ and more often triggered by 
emotional and socio-cultural factors than SZ and/or SFD.  
Lee et al. [63] BPD exhibits fewer schizoid and schizotypal traits, and better social and 
occupational functioning than SZ. 
Study Symptom measures and cognitive dysfunctions 
Korver-Nieberg 
et al. [58] 
Cross-sectional study showing shorter duration, less emotional distress, fewer 
negative and disorganized symptoms, and higher quality of life in BPD than SZ 
and related disorders. 
Ngoma et al. 
[62] 
BPD differs from both SZ and SFD in terms of cognitive and social functioning, 
positive symptoms and excitement.  
Lee et al. [63] Symptoms are less severe in BPD than SZ, but no difference in attention, 
memory and executive function.  
Lyne et al. 
[75] 
Negative symptoms were significantly fewer in BPD than in SZ spectrum 
disorders.  
Ngoma et al. 
[76] 
Although patients with BPD, SZ and SFD were more severely impaired than 
healthy controls, no selective deficit was found. 
Ayesa-Arriola 
et al. [77] 
BPD patients improved more rapidly than those with SZ, SFD and psychosis 
NOS after six months.  
 Diagnostic stability, course and outcome 
Schwartz et al. 
[56]* 
3/11 cases (27%) first admitted with BPD did not change diagnosis after 2 
years. 
Salvatore et al. 
[57]* 
22/36 cases (61%) with BPD did not develop another diagnosis after 2 years.    
Kingston et al. 
[59]* 
Many cases with BPD had rapid remission after the initial episode, but 80% 
developed longer lasting psychotic and affective disorders over 6 years.    
Heslin et al. 
[60]* 
3/13 cases (23%) with BPD retained the same diagnosis after 8 or more years. 
Schimmelmann 
et al. [91]* 
8/11 cases (73%) with BPD did not change diagnosis at 18 months follow-up.   
Rahm & 
Culberg [92]* 
Two-thirds of cases with BPD (n = 21) recovered; the remaining patients 
developed mainly SZ and/or affective psychosis over 3 years.      
Haahr et al. 
[93]* 
Diagnostic stability of BPD (n =20) reduced from 75% after the first year to 
60% after 2 years; most transitions were to SZ and/or affective disorders.      
Rufino et al. 
[94]* 
7/31 cases (23%) with BPD from an emergency service did not change 
diagnosis after 15 months; no difference in clinical and functional outcome 
from SFD and affective disorders.    
Subramaniam 
et al. [95]* 
4/13 cases (31%) with BPD did not change diagnosis: short hospital stay and 
high premorbid functioning predicted diagnostic stability.   
Pillmann et al. 
[96] 
23 admissions with BPD had high rates of relapse but significantly better 
clinical and social outcomes than patients with SZ over 2.5 years.    
 Response to treatment 
Ehlis et al. 
[100] 
Atypical neuroleptics seem to have a positive effect on prefrontal brain 
functions.  
Table
 
*First-admission/episode psychosis study;  
BPD: brief psychotic disorder; SFD: psychosis NOS: not otherwise specified; schizophreniform 
disorder; SZ: schizophrenia.  
 
